勘误：基于一项组织和液体活检的临床多中心研究，携带TP53 R273C或KRAS G12V的EGFR T790M晚期非小细胞肺癌患者无法从奥希替尼中获益。
Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy.
作者信息
Fu Yulong, Wang Anqi, Zhou Jieqi, Feng Wei, Shi Minhua, Xu Xiao, Zhao Hongqing, Cai Liming, Feng Jian, Lv Xuedong, Zhang Xiaodong, Xu Wenjing, Zhang Zhengrong, Ma Guoer, Wang Jian, Zhou Tong, Zhao Dahai, Fang Haohui, Liu Zeyi, Huang Jian-An
机构信息
Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Suzhou Key Laboratory for Respiratory Diseases, Suzhou, China.
出版信息
Front Oncol. 2023 Jun 27;13:1236311. doi: 10.3389/fonc.2023.1236311. eCollection 2023.
Abstract
[This corrects the article DOI: 10.3389/fonc.2021.621992.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fonc.2021.621992。]
相似文献
1
Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy.
Front Oncol. 2023 Jun 27;13:1236311. doi: 10.3389/fonc.2023.1236311. eCollection 2023.
2
Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy.
Front Oncol. 2021 Feb 24;11:621992. doi: 10.3389/fonc.2021.621992. eCollection 2021.
3
Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients.
Cancers (Basel). 2022 Oct 18;14(20):5095. doi: 10.3390/cancers14205095.
4
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
J Cancer Res Clin Oncol. 2020 Sep;146(9):2427-2433. doi: 10.1007/s00432-020-03239-1. Epub 2020 May 8.
5
Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Thorac Cancer. 2020 Jan;11(1):140-149. doi: 10.1111/1759-7714.13255. Epub 2019 Nov 22.
6
Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.
Mol Oncol. 2019 May;13(5):1226-1234. doi: 10.1002/1878-0261.12481. Epub 2019 Apr 10.
7
Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Cancer Sci. 2021 Sep;112(9):3784-3795. doi: 10.1111/cas.15035. Epub 2021 Jul 22.
8
Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Clin Oncol (R Coll Radiol). 2022 Nov;34(11):e451-e462. doi: 10.1016/j.clon.2022.06.003. Epub 2022 Jul 7.
9
Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Cancer. 2020 Jan 1;126(9):1940-1948. doi: 10.1002/cncr.32749. Epub 2020 Feb 5.
10
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
Lung Cancer. 2018 Jan;115:21-27. doi: 10.1016/j.lungcan.2017.11.011. Epub 2017 Nov 13.
Zotero 插件